Characterization of Polymyxin B-Induced Nephrotoxicity: Implications for Dosing Regimen Design
暂无分享,去创建一个
Ming Hu | Vincent H. Tam | L. Truong | V. Tam | Taijun Yin | Kamilia Abdelraouf | Luan D. Truong | Kamilia Abdelraouf | Kirk H. Braggs | Taijun Yin | Ming Hu
[1] K. Liewendahl,et al. THE THERAPEUTIC SUCCESS AND NEPHROTOXICITY OF COLISTIN IN ACUTE AND CHRONIC NEPHROPATHIES WITH IMPAIRED RENAL FUNCTION. , 2009, Acta medica Scandinavica.
[2] A Forrest,et al. Population Pharmacokinetics of Colistin Methanesulfonate and Formed Colistin in Critically Ill Patients from a Multicenter Study Provide Dosing Suggestions for Various Categories of Patients , 2011, Antimicrobial Agents and Chemotherapy.
[3] G. Drusano,et al. Larger Vancomycin Doses (at Least Four Grams per Day) Are Associated with an Increased Incidence of Nephrotoxicity , 2008, Antimicrobial Agents and Chemotherapy.
[4] G. Drusano,et al. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[5] V. Tam,et al. Nephrotoxicity of continuous versus intermittent infusion of vancomycin in outpatient parenteral antimicrobial therapy. , 2009, International journal of antimicrobial agents.
[6] D. Landman,et al. Citywide emergence of Pseudomonas aeruginosa strains with reduced susceptibility to polymyxin B. , 2005, The Journal of antimicrobial chemotherapy.
[7] K. Kaye,et al. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[8] G. Drusano,et al. Back to the future: using aminoglycosides again and how to dose them optimally. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[9] V. Tam,et al. Risk factors for nephrotoxicity associated with continuous vancomycin infusion in outpatient parenteral antibiotic therapy. , 2008, The Journal of antimicrobial chemotherapy.
[10] R. Katz. RENAL AND POSSIBLY HEPATIC TOXICITY FROM COLY-MYCIN. REPORT OF A CASE. , 1963, The Medical annals of the District of Columbia.
[11] M. Falagas,et al. Effectiveness and nephrotoxicity of colistin monotherapy vs. colistin-meropenem combination therapy for multidrug-resistant Gram-negative bacterial infections. , 2006, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[12] V. Tam,et al. Polymyxin B: a new strategy for multidrug-resistant Gram-negative organisms , 2008, Expert opinion on investigational drugs.
[13] E. Federman,et al. Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy. , 1970, Annals of internal medicine.
[14] V. Tam,et al. Polymyxin B: a new strategy for multidrug-resistant Gram-negative organisms. , 2008, Expert opinion on investigational drugs.
[15] C. Lang,et al. Fixatives and methods of fixation in selected tissues of the laboratory rat. , 1978, Clinical toxicology.
[16] D. Graham,et al. Effects of Large Doses of Colistin Sulphomethate Sodium on Renal Function , 1970, British medical journal.
[17] Russell E. Lewis,et al. Pharmacodynamics of Polymyxin B against Pseudomonas aeruginosa , 2005, Antimicrobial Agents and Chemotherapy.
[18] L. Rice. Emerging issues in the management of infections caused by multidrug-resistant gram-negative bacteria. , 2007, Cleveland Clinic journal of medicine.
[19] G. Turett,et al. Polymyxin B Nephrotoxicity and Efficacy against Nosocomial Infections Caused by Multiresistant Gram-Negative Bacteria , 2003, Antimicrobial Agents and Chemotherapy.
[20] J. Garnacho-Montero,et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[21] S. Moestrup,et al. Evidence that epithelial glycoprotein 330/megalin mediates uptake of polybasic drugs. , 1995, The Journal of clinical investigation.
[22] J. Turnidge,et al. Subacute Toxicity of Colistin Methanesulfonate in Rats: Comparison of Various Intravenous Dosage Regimens , 2008, Antimicrobial Agents and Chemotherapy.
[23] M. Falagas,et al. Polymyxins: a review of the current status including recent developments. , 2008, Annals of the Academy of Medicine, Singapore.
[24] G. Striker,et al. Colistimethate toxicity. Report of a fatal case in a previously healthy child. , 1969, JAMA.
[25] S. Hammer,et al. Combination therapy with polymyxin B for the treatment of multidrug-resistant Gram-negative respiratory tract infections. , 2004, The Journal of antimicrobial chemotherapy.
[26] K. Ko,et al. High rates of resistance to colistin and polymyxin B in subgroups of Acinetobacter baumannii isolates from Korea. , 2007, The Journal of antimicrobial chemotherapy.
[27] J. Low,et al. Pharmacokinetics of polymyxin B1 in patients with multidrug-resistant Gram-negative bacterial infections. , 2008, Diagnostic microbiology and infectious disease.
[28] G. Drusano,et al. Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.